Your AI-Trained Oncology Knowledge Connection!
Paolo Tarantino, MD, gives an overview on how the recently approved combination of capivasertib plus fulvestrant can help improve treatment strategies for patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer
Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.
First-line pembrolizumab plus chemotherapy has been approved by the FDA for patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Experts in the multiple myeloma space met to discuss the treatment and monitoring after bispecific antibodies.
The progression-free survival benefit of dostarlimab and chemotherapy extends to those with mismatch repair deficient or microsatellite instability–high advanced endometrial cancer.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
Radical hysterectomies result in worse symptom experience, body image, menopausal symptoms, sexual worry, sex activity and enjoyment compared with simple hysterectomy in those with early-stage cervical cancer.
Data from the phase 1/2 TRIDENT-1 trial support the FDA approval of repotrectinib for those with ROS1-positive advanced or metastatic non–small cell lung cancer.
Progression-free survival benefit appears consistent in patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin.
Combining atezolizumab with bevacizumab and chemotherapy may be a new frontline therapy option for patients with metastatic, persistent or recurrent cervical cancer, says Ana Oaknin, MD, PhD.
Use of the surgical Epione robot will save a significant amount of time when performing surgery for patients with liver tumors and potentially other cancers, says Govindarajan Narayanan, MD.
The preliminary safety and efficacy of SONALA-001 is being assessed as part of the SDT-201 study in diffuse intrinsic pontine glioma.
Approval of PD-L1 IHC 22C3 pharmDx may also identify patients with non–small cell lung cancer and other malignancies who may benefit from treatment with pembrolizumab.
Asher A. Chanan-Khan, MBBS, MD, led a panel discussion surround the use of Bruton tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia.
Investigators report that loss of MMR mechanism is not predictive of response to chemotherapy or pembrolizumab in patients with stage III or IVA, stage IVB, or recurrent endometrial cancer.
A case study by Sahith Kumar Shetty, BDS, MDS, et al reviews the need for a multidisciplinary approach to the treatment of patients with Gorlin-Goltz syndrome.
Data from the phase 3 KEYNOTE-A18 study may support pembrolizumab plus chemoradiotherapy as a new standard of care for those with newly diagnosed, high-risk, locally advanced cervical cancer.
Data from the phase 3 CHRONOS-4 study highlight that copanlisib did not reach the primary end point of progression-free survival among patients with relapsed follicular lymphoma.
Durvalumab plus olaparib, durvalumab monotherapy, or chemotherapy plus durvalumab saw an improvement in progression-free survival for patients with newly diagnosed advanced or recurrent endometrial cancer.
The safety profile of durvalumab plus TACE and bevacizumab in patients with hepatocellular carcinoma in the phase 3 EMERALD-1 study appears to consistent with previous findings.
Adagrasib, which now has a positive CHMP opinion, was previously examined as part of the phase 1/2 KRYSTAL-1 study.
If momelotinib receives approval in the European Union, it will become the only agent for the treatment of myelofibrosis coupled with moderate to severe anemia.
Karmanos Cancer Institute and Cleveland Clinic gave presentations regarding treatment of multiple myeloma and chronic myeloid leukemia in the latest Face Off.
Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.
Radiographic progression-free survival outcomes with olaparib plus abiraterone acetate and prednisone appear to be consistent with prior analyses of the phase 3 PROpel trial.
Sara M. Tolaney, MD, MPH, gives an extensive overview on the current breast cancer landscape and available treatment options.
Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discussed how to best mitigate adverse effects in patients with non–small cell lung cancer.
Arvind N. Dasari, MD, lead investigator of the FRESCO-2 trial, spoke about the recent approval of fruquintinib for patients with previously treated metastatic colorectal cancer.
The 3-year PFS rate for patients with MCL was 94%, and the OS rate was 97%
Continued manufacturing of methotrexate may improve access to chemotherapy for patients with breast cancer, lung cancer, and other malignancies in the United States.
